O	0	8	Impaired	Impaired	JJ	B-NP
O	9	12	CK1	CK1	NN	I-NP
O	13	18	delta	delta	NN	I-NP
O	19	27	activity	activity	NN	I-NP
O	28	38	attenuates	attenuate	VBZ	B-VP
O	39	43	SV40	SV40	NN	B-NP
O	43	44	-	-	HYPH	O
O	44	51	induced	induce	VBN	B-NP
B-Cell	52	60	cellular	cellular	JJ	I-NP
O	61	75	transformation	transformation	NN	I-NP
O	76	78	in	in	FW	B-ADVP
O	79	84	vitro	vitro	FW	I-ADVP
O	85	88	and	and	CC	O
O	89	94	mouse	mouse	NN	B-NP
B-Organ	95	102	mammary	mammary	JJ	I-NP
O	103	117	carcinogenesis	carcinogenesis	NN	I-NP
O	118	120	in	in	FW	B-ADVP
O	121	125	vivo	vivo	FW	I-ADVP
O	125	126	.	.	.	O

O	128	134	Simian	Simian	JJ	B-NP
O	135	140	virus	virus	NN	I-NP
O	141	143	40	40	CD	I-NP
O	144	145	(	(	(	O
O	145	149	SV40	SV40	NN	B-NP
O	149	150	)	)	)	O
O	151	153	is	be	VBZ	B-VP
O	154	155	a	a	DT	B-NP
O	156	164	powerful	powerful	JJ	I-NP
O	165	169	tool	tool	NN	I-NP
O	170	172	to	to	TO	B-VP
O	173	178	study	study	VB	I-VP
B-Cell	179	187	cellular	cellular	JJ	B-NP
O	188	202	transformation	transformation	NN	I-NP
O	203	205	in	in	FW	B-ADVP
O	206	211	vitro	vitro	FW	I-ADVP
O	211	212	,	,	,	O
O	213	215	as	as	RB	B-CONJP
O	216	220	well	well	RB	I-CONJP
O	221	223	as	as	IN	I-CONJP
B-Cancer	224	229	tumor	tumor	NN	B-NP
O	230	241	development	development	NN	I-NP
O	242	245	and	and	CC	O
O	246	257	progression	progression	NN	B-NP
O	258	260	in	in	FW	B-ADVP
O	261	265	vivo	vivo	FW	I-ADVP
O	265	266	.	.	.	O

O	267	274	Various	Various	JJ	B-NP
B-Cell	275	283	cellular	cellular	JJ	I-NP
O	284	291	kinases	kinase	NNS	I-NP
O	291	292	,	,	,	O
O	293	298	among	among	IN	B-PP
O	299	303	them	them	PRP	B-NP
O	304	311	members	member	NNS	B-NP
O	312	314	of	of	IN	B-PP
O	315	318	the	the	DT	B-NP
O	319	322	CK1	CK1	NN	I-NP
O	323	329	family	family	NN	I-NP
O	329	330	,	,	,	O
O	331	335	play	play	VBP	B-VP
O	336	338	an	an	DT	B-NP
O	339	348	important	important	JJ	I-NP
O	349	353	role	role	NN	I-NP
O	354	356	in	in	IN	B-PP
O	357	367	modulating	modulate	VBG	B-VP
O	368	371	the	the	DT	B-NP
O	372	384	transforming	transform	VBG	I-NP
O	385	393	activity	activity	NN	I-NP
O	394	396	of	of	IN	B-PP
O	397	401	SV40	SV40	NN	B-NP
O	401	402	,	,	,	O
O	403	412	including	include	VBG	B-PP
O	413	416	the	the	DT	B-NP
O	417	429	transforming	transform	VBG	I-NP
O	430	438	activity	activity	NN	I-NP
O	439	441	of	of	IN	B-PP
O	442	443	T	T	NN	B-NP
O	443	444	-	-	HYPH	B-NP
O	444	446	Ag	Ag	NN	I-NP
O	446	447	,	,	,	O
O	448	451	the	the	DT	B-NP
O	452	457	major	major	JJ	I-NP
O	458	470	transforming	transform	VBG	I-NP
O	471	478	protein	protein	NN	I-NP
O	479	481	of	of	IN	B-PP
O	482	486	SV40	SV40	NN	B-NP
O	486	487	,	,	,	O
O	488	494	itself	itself	PRP	B-NP
O	494	495	.	.	.	O

O	496	500	Here	Here	RB	B-ADVP
O	501	503	we	we	PRP	B-NP
O	504	517	characterized	characterize	VBD	B-VP
O	518	521	the	the	DT	B-NP
O	522	529	effects	effect	NNS	I-NP
O	530	532	of	of	IN	B-PP
O	533	539	mutant	mutant	JJ	B-NP
O	540	548	CK1delta	CK1delta	NN	I-NP
O	549	557	variants	variant	NNS	I-NP
O	558	562	with	with	IN	B-PP
O	563	571	impaired	impaired	JJ	B-NP
O	572	578	kinase	kinase	NN	I-NP
O	579	587	activity	activity	NN	I-NP
O	588	590	on	on	IN	B-PP
O	591	595	SV40	SV40	NN	B-NP
O	595	596	-	-	HYPH	B-NP
O	596	603	induced	induce	VBN	I-NP
B-Cell	604	608	cell	cell	NN	I-NP
O	609	623	transformation	transformation	NN	I-NP
O	624	626	in	in	FW	B-ADVP
O	627	632	vitro	vitro	FW	I-ADVP
O	632	633	,	,	,	B-PP
O	634	637	and	and	CC	I-PP
O	638	640	on	on	IN	B-PP
O	641	645	SV40	SV40	NN	B-NP
O	645	646	-	-	HYPH	B-NP
O	646	653	induced	induce	VBN	I-NP
B-Organ	654	661	mammary	mammary	JJ	I-NP
O	662	676	carcinogenesis	carcinogenesis	NN	I-NP
O	677	679	in	in	FW	B-ADVP
O	680	684	vivo	vivo	FW	I-ADVP
O	685	687	in	in	IN	B-PP
O	688	689	a	a	DT	B-NP
O	690	700	transgenic	transgenic	JJ	I-NP
O	700	701	/	/	SYM	I-NP
O	701	703	bi	bi	AFX	I-NP
O	703	704	-	-	HYPH	I-NP
O	704	714	transgenic	transgenic	JJ	I-NP
O	715	720	mouse	mouse	NN	I-NP
O	721	726	model	model	NN	I-NP
O	726	727	.	.	.	O

O	728	736	CK1delta	CK1delta	NN	B-NP
O	737	744	mutants	mutant	NNS	I-NP
O	745	754	exhibited	exhibit	VBD	B-VP
O	755	756	a	a	DT	B-NP
O	757	764	reduced	reduce	VBN	I-NP
O	765	771	kinase	kinase	NN	I-NP
O	772	780	activity	activity	NN	I-NP
O	781	789	compared	compare	VBN	B-VP
O	790	792	to	to	TO	B-PP
O	793	803	wtCK1delta	wtCK1delta	NN	B-NP
O	804	806	in	in	IN	B-PP
O	807	809	in	in	FW	B-NP
O	810	815	vitro	vitro	FW	I-NP
O	816	822	kinase	kinase	NN	I-NP
O	823	829	assays	assay	NNS	I-NP
O	829	830	.	.	.	O

O	831	840	Molecular	Molecular	JJ	B-NP
O	841	849	modeling	modeling	NN	I-NP
O	850	857	studies	study	NNS	I-NP
O	858	867	suggested	suggest	VBD	B-VP
O	868	872	that	that	IN	B-SBAR
O	873	881	mutation	mutation	NN	B-NP
O	882	887	N172D	N172D	NN	I-NP
O	887	888	,	,	,	O
O	889	896	located	located	JJ	B-ADJP
O	897	903	within	within	IN	B-PP
O	904	907	the	the	DT	B-NP
O	908	917	substrate	substrate	NN	I-NP
O	918	925	binding	binding	NN	I-NP
O	926	932	region	region	NN	I-NP
O	932	933	,	,	,	O
O	934	936	is	be	VBZ	B-VP
O	937	943	mainly	mainly	RB	B-ADJP
O	944	955	responsible	responsible	JJ	I-ADJP
O	956	959	for	for	IN	B-PP
O	960	968	impaired	impaired	JJ	B-NP
O	969	980	mutCK1delta	mutCK1delta	NN	I-NP
O	981	989	activity	activity	NN	I-NP
O	989	990	.	.	.	O

O	991	995	When	When	WRB	B-ADVP
O	996	1002	stably	stably	RB	B-ADVP
O	1003	1007	over	over	RB	I-ADVP
O	1007	1008	-	-	HYPH	B-NP
O	1008	1017	expressed	express	VBN	B-VP
O	1018	1020	in	in	IN	B-PP
O	1021	1028	maximal	maximal	JJ	B-NP
O	1029	1040	transformed	transform	VBN	I-NP
B-Cell	1041	1043	SV	SV	NN	I-NP
I-Cell	1043	1044	-	-	HYPH	I-NP
I-Cell	1044	1046	52	52	CD	I-NP
I-Cell	1047	1052	cells	cell	NNS	I-NP
O	1052	1053	,	,	,	O
O	1054	1062	CK1delta	CK1delta	NN	B-NP
O	1063	1070	mutants	mutant	NNS	I-NP
O	1071	1078	induced	induce	VBD	B-VP
O	1079	1088	reversion	reversion	NN	B-NP
O	1089	1091	to	to	TO	B-PP
O	1092	1093	a	a	DT	B-NP
O	1094	1101	minimal	minimal	JJ	I-NP
O	1102	1113	transformed	transform	VBN	I-NP
O	1114	1123	phenotype	phenotype	NN	I-NP
O	1124	1126	by	by	IN	B-PP
O	1127	1135	dominant	dominant	JJ	B-NP
O	1135	1136	-	-	HYPH	I-NP
O	1136	1144	negative	negative	JJ	I-NP
O	1145	1157	interference	interference	NN	I-NP
O	1158	1162	with	with	IN	B-PP
O	1163	1173	endogenous	endogenous	JJ	B-NP
O	1174	1184	wtCK1delta	wtCK1delta	NN	I-NP
O	1184	1185	.	.	.	O

O	1186	1188	To	To	TO	B-VP
O	1189	1201	characterize	characterize	VB	I-VP
O	1202	1205	the	the	DT	B-NP
O	1206	1213	effects	effect	NNS	I-NP
O	1214	1216	of	of	IN	B-PP
O	1217	1225	CK1delta	CK1delta	NN	B-NP
O	1226	1228	on	on	IN	B-PP
O	1229	1233	SV40	SV40	NN	B-NP
O	1233	1234	-	-	HYPH	B-NP
O	1234	1241	induced	induce	VBN	I-NP
B-Organ	1242	1249	mammary	mammary	JJ	I-NP
O	1250	1264	carcinogenesis	carcinogenesis	NN	I-NP
O	1264	1265	,	,	,	O
O	1266	1268	we	we	PRP	B-NP
O	1269	1278	generated	generate	VBD	B-VP
O	1279	1289	transgenic	transgenic	JJ	B-NP
O	1290	1294	mice	mouse	NNS	I-NP
O	1295	1305	expressing	express	VBG	B-VP
O	1306	1312	mutant	mutant	JJ	B-NP
O	1313	1321	CK1delta	CK1delta	NN	I-NP
O	1322	1327	under	under	IN	B-PP
O	1328	1331	the	the	DT	B-NP
O	1332	1339	control	control	NN	I-NP
O	1340	1342	of	of	IN	B-PP
O	1343	1346	the	the	DT	B-NP
O	1347	1351	whey	whey	JJ	I-NP
O	1352	1358	acidic	acidic	JJ	I-NP
O	1359	1366	protein	protein	NN	I-NP
O	1367	1368	(	(	(	O
O	1368	1371	WAP	WAP	NN	B-NP
O	1371	1372	)	)	)	O
O	1373	1377	gene	gene	NN	B-NP
O	1378	1386	promoter	promoter	NN	I-NP
O	1386	1387	,	,	,	O
O	1388	1391	and	and	CC	O
O	1392	1399	crossed	cross	VBD	B-VP
O	1400	1404	them	them	PRP	B-NP
O	1405	1409	with	with	IN	B-PP
O	1410	1414	SV40	SV40	NN	B-NP
O	1415	1425	transgenic	transgenic	JJ	I-NP
O	1426	1429	WAP	WAP	NN	I-NP
O	1429	1430	-	-	HYPH	B-NP
O	1430	1431	T	T	NN	I-NP
O	1431	1432	-	-	HYPH	O
O	1432	1439	antigen	antigen	NN	B-NP
O	1440	1441	(	(	(	O
O	1441	1444	WAP	WAP	NN	B-NP
O	1444	1445	-	-	HYPH	I-NP
O	1445	1446	T	T	NN	I-NP
O	1446	1447	)	)	)	I-NP
O	1448	1452	mice	mouse	NNS	I-NP
O	1452	1453	.	.	.	O

O	1454	1458	Both	Both	CC	O
O	1459	1462	WAP	WAP	NN	B-NP
O	1462	1463	-	-	HYPH	I-NP
O	1463	1464	T	T	NN	I-NP
O	1465	1469	mice	mouse	NNS	I-NP
O	1470	1472	as	as	RB	B-CONJP
O	1473	1477	well	well	RB	I-CONJP
O	1478	1480	as	as	IN	I-CONJP
O	1481	1484	WAP	WAP	NN	B-NP
O	1484	1485	-	-	HYPH	I-NP
O	1485	1496	mutCK1delta	mutCK1delta	NN	I-NP
O	1496	1497	/	/	SYM	B-NP
O	1497	1500	WAP	WAP	NN	I-NP
O	1500	1501	-	-	HYPH	I-NP
O	1501	1502	T	T	NN	I-NP
O	1503	1505	bi	bi	AFX	B-NP
O	1505	1506	-	-	HYPH	I-NP
O	1506	1516	transgenic	transgenic	JJ	I-NP
O	1517	1521	mice	mouse	NNS	I-NP
O	1522	1531	developed	develop	VBD	B-VP
B-Cancer	1532	1538	breast	breast	NN	B-NP
I-Cancer	1539	1545	cancer	cancer	NN	I-NP
O	1545	1546	.	.	.	O

O	1547	1554	However	However	RB	B-ADVP
O	1554	1555	,	,	,	O
B-Cancer	1556	1561	tumor	tumor	NN	B-NP
O	1562	1571	incidence	incidence	NN	I-NP
O	1572	1575	was	be	VBD	B-VP
O	1576	1581	lower	low	JJR	B-ADJP
O	1582	1585	and	and	CC	O
O	1586	1590	life	life	NN	B-NP
O	1591	1595	span	span	NN	I-NP
O	1596	1599	was	be	VBD	B-VP
O	1600	1613	significantly	significantly	RB	B-ADVP
O	1614	1620	longer	longer	RBR	I-ADVP
O	1621	1623	in	in	IN	B-PP
O	1624	1627	WAP	WAP	NN	B-NP
O	1627	1628	-	-	HYPH	B-NP
O	1628	1639	mutCK1delta	mutCK1delta	NN	I-NP
O	1639	1640	/	/	SYM	B-NP
O	1640	1643	WAP	WAP	NN	I-NP
O	1643	1644	-	-	HYPH	I-NP
O	1644	1645	T	T	NN	I-NP
O	1646	1648	bi	bi	AFX	B-NP
O	1648	1649	-	-	HYPH	I-NP
O	1649	1659	transgenic	transgenic	JJ	I-NP
O	1660	1667	animals	animal	NNS	I-NP
O	1667	1668	.	.	.	O

O	1669	1672	The	The	DT	B-NP
O	1673	1680	reduced	reduce	VBN	I-NP
O	1681	1689	CK1delta	CK1delta	NN	I-NP
O	1690	1698	activity	activity	NN	I-NP
O	1699	1702	did	do	VBD	B-VP
O	1703	1706	not	not	RB	I-VP
O	1707	1713	affect	affect	VB	I-VP
O	1714	1719	early	early	JJ	B-NP
B-Pathological_formation	1720	1726	lesion	lesion	NN	I-NP
O	1727	1736	formation	formation	NN	I-NP
O	1737	1743	during	during	IN	B-PP
O	1744	1757	tumorigenesis	tumorigenesis	NN	B-NP
O	1757	1758	,	,	,	O
O	1759	1769	suggesting	suggest	VBG	B-VP
O	1770	1774	that	that	IN	B-SBAR
O	1775	1783	impaired	impaired	JJ	B-NP
O	1784	1792	CK1delta	CK1delta	NN	I-NP
O	1793	1801	activity	activity	NN	I-NP
O	1802	1809	reduces	reduce	VBZ	B-VP
O	1810	1813	the	the	DT	B-NP
O	1814	1825	probability	probability	NN	I-NP
O	1826	1829	for	for	IN	B-PP
O	1830	1839	outgrowth	outgrowth	NN	B-NP
O	1840	1842	of	of	IN	B-PP
B-Cancer	1843	1845	in	in	FW	B-NP
I-Cancer	1846	1850	situ	situ	FW	I-NP
I-Cancer	1851	1861	carcinomas	carcinoma	NNS	I-NP
O	1862	1864	to	to	TO	B-PP
B-Cancer	1865	1873	invasive	invasive	JJ	B-NP
I-Cancer	1874	1884	carcinomas	carcinoma	NNS	I-NP
O	1884	1885	.	.	.	O

O	1886	1889	The	The	DT	B-NP
O	1890	1899	different	different	JJ	I-NP
O	1900	1911	tumorigenic	tumorigenic	JJ	I-NP
O	1912	1921	potential	potential	NN	I-NP
O	1922	1924	of	of	IN	B-PP
O	1925	1929	SV40	SV40	NN	B-NP
O	1930	1932	in	in	IN	B-PP
O	1933	1936	WAP	WAP	NN	B-NP
O	1936	1937	-	-	HYPH	I-NP
O	1937	1938	T	T	NN	I-NP
O	1939	1942	and	and	CC	I-NP
O	1943	1946	WAP	WAP	NN	I-NP
O	1946	1947	-	-	HYPH	B-NP
O	1947	1958	mutCK1delta	mutCK1delta	NN	I-NP
O	1958	1959	/	/	SYM	B-NP
O	1959	1962	WAP	WAP	NN	I-NP
O	1962	1963	-	-	HYPH	I-NP
O	1963	1964	T	T	NN	I-NP
B-Cancer	1965	1971	tumors	tumor	NNS	I-NP
O	1972	1975	was	be	VBD	B-VP
O	1976	1980	also	also	RB	I-VP
O	1981	1990	reflected	reflect	VBN	I-VP
O	1991	1993	by	by	IN	B-PP
O	1994	1995	a	a	DT	B-NP
O	1996	2009	significantly	significantly	RB	I-NP
O	2010	2019	different	different	JJ	I-NP
O	2020	2030	expression	expression	NN	I-NP
O	2031	2033	of	of	IN	B-PP
O	2034	2041	various	various	JJ	B-NP
O	2042	2047	genes	gene	NNS	I-NP
O	2048	2053	known	know	VBN	B-VP
O	2054	2056	to	to	TO	I-VP
O	2057	2059	be	be	VB	I-VP
O	2060	2068	involved	involve	VBN	I-VP
O	2069	2071	in	in	IN	B-PP
B-Cancer	2072	2077	tumor	tumor	NN	B-NP
O	2078	2089	progression	progression	NN	I-NP
O	2089	2090	,	,	,	O
O	2091	2103	specifically	specifically	RB	B-ADVP
O	2104	2106	of	of	IN	B-PP
O	2107	2112	those	those	DT	B-NP
O	2113	2121	involved	involve	VBN	B-VP
O	2122	2124	in	in	IN	B-PP
O	2125	2128	wnt	wnt	NN	B-NP
O	2128	2129	-	-	HYPH	B-NP
O	2129	2138	signaling	signaling	NN	I-NP
O	2139	2142	and	and	CC	I-NP
O	2143	2146	DNA	DNA	NN	I-NP
O	2147	2153	repair	repair	NN	I-NP
O	2153	2154	.	.	.	O

O	2155	2158	Our	Our	PRP$	B-NP
O	2159	2163	data	datum	NNS	I-NP
O	2164	2168	show	show	VBP	B-VP
O	2169	2173	that	that	IN	B-SBAR
O	2174	2186	inactivating	inactivate	VBG	B-VP
O	2187	2196	mutations	mutation	NNS	B-NP
O	2197	2199	in	in	IN	B-PP
O	2200	2208	CK1delta	CK1delta	NN	B-NP
O	2209	2215	impair	impair	NN	I-NP
O	2216	2220	SV40	SV40	NN	I-NP
O	2220	2221	-	-	HYPH	O
O	2221	2228	induced	induce	VBN	B-NP
B-Cell	2229	2237	cellular	cellular	JJ	I-NP
O	2238	2252	transformation	transformation	NN	I-NP
O	2253	2255	in	in	FW	B-ADVP
O	2256	2261	vitro	vitro	FW	I-ADVP
O	2262	2265	and	and	CC	O
O	2266	2271	mouse	mouse	NN	B-NP
B-Organ	2272	2279	mammary	mammary	JJ	I-NP
O	2280	2294	carcinogenesis	carcinogenesis	NN	I-NP
O	2295	2297	in	in	FW	B-ADVP
O	2298	2302	vivo	vivo	FW	I-ADVP
O	2302	2303	.	.	.	O

